Skip to main content

Advertisement

SpringerLink
Log in

Noninvasive Neuromodulation in Migraine

  • Episodic Migraine (S Nahas, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The past two decades has seen an influx of noninvasive neuromodulation devices aimed at treatment of various primary headache disorders, including cluster headache and migraine. This narrative review is to summarize the current options in noninvasive neuromodulation in migraine.

Recent Findings

A variety of noninvasive neuromodulation devices have been FDA cleared and marketed for use in migraine, including single-pulse transcranial magnetic stimulation (sTMS), noninvasive vagal nerve stimulators (nVNS), and external trigeminal nerve stimulators (eTNS). Newer devices include peripheral electrical stimulation devices (PES), caloric stimulation, and others. Each has varying levels of evidence supporting its use in migraine, tolerability profiles, and access issues.

Summary

Noninvasive neuromodulation devices can be beneficial when used in patients with migraine, with minimal side effects. As more devices are developed, approved, and marketed in the future, rigorous research on efficacy and safety remain a top priority.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496–505.

    PubMed  Google Scholar 

  2. Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(8):1278–99.

    PubMed  Google Scholar 

  3. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.

    Google Scholar 

  4. Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159–69.

    PubMed  Google Scholar 

  5. Halker Singh RB, Ailani J, Robbins MS. Neuromodulation for the acute and preventive therapy of migraine and cluster headache. Headache. 2019;59(S2):33–49.

    PubMed  Google Scholar 

  6. Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain J Neurol. 2019;142(7):1894–904.

    Google Scholar 

  7. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Deng H, Li G, Nie H, Feng Y, Guo G, Guo W, et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis. BMC Neurol. 2020;20(1):57.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Yang Y, Chen M, Sun Y, Gao B, Chen Z, Wang Z. Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs. 34:463–71.

  10. Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache. 2020;60(4):686–700.

    PubMed  PubMed Central  Google Scholar 

  12. Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation. 1999;2(3):217–21.

    CAS  PubMed  Google Scholar 

  13. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet. 1985;325(8437):1106–7 Important to understand the mechanism underlying sTMS.

    Google Scholar 

  14. Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain. 2016;139(7):2002–14 Important to understand the mechanism underlying sTMS.

    PubMed  PubMed Central  Google Scholar 

  15. Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373–80 Important trial for approval of sTMS for acute therapy.

    PubMed  Google Scholar 

  16. Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015;16:535.

    PubMed  Google Scholar 

  17. Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018;38(6):1038–48 Important trial for approval of sTMS for preventive therapy.

    PubMed  PubMed Central  Google Scholar 

  18. Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: a safety review. Headache. 2010;50(7):1153–63 Important to understand the safety of sTMS.

    PubMed  Google Scholar 

  19. Simon B, Blake J. Mechanism of action of non-invasive cervical vagus nerve stimulation for the treatment of primary headaches. Am J Manag Care. 2017;23(17):S312–6 Important to understand the mechanism underlying nVNS.

    PubMed  Google Scholar 

  20. Henssen DJHA, Derks B, van Doorn M, Verhoogt N, Van Cappellen van Walsum A-M, Staats P, et al. Vagus nerve stimulation for primary headache disorders: An anatomical review to explain a clinical phenomenon. Cephalalgia. 2019;39(9):1180–94 Important to understand the mechanism underlying nVNS.

    PubMed  PubMed Central  Google Scholar 

  21. Zhang Y, Liu J, Li H, Yan Z, Liu X, Cao J, et al. Transcutaneous auricular vagus nerve stimulation at 1 Hz modulates locus coeruleus activity and resting state functional connectivity in patients with migraine: an fMRI study. NeuroImage. 2019;24:101971.

    PubMed  Google Scholar 

  22. Goadsby P, Grosberg B, Mauskop A, Cady R, Simmons K. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014;34(12):986–93.

    CAS  PubMed  Google Scholar 

  23. Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018;91(4):e364–73 Important trial used for approval of nVNS for acute therapy.

    PubMed  PubMed Central  Google Scholar 

  24. Grazzi L, Tassorelli C, de Tommaso M, Pierangeli G, Martelletti P, Rainero I, et al. Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. J Headache Pain. 2018;19(1):98.

    PubMed  PubMed Central  Google Scholar 

  25. Martelletti P, Barbanti P, Grazzi L, Pierangeli G, Rainero I, Geppetti P, et al. Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. J Headache Pain. 2018;19(1):101.

    PubMed  PubMed Central  Google Scholar 

  26. Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation. Neurology. 2016;87(5):529–38.

    PubMed  PubMed Central  Google Scholar 

  27. Diener H-C, Goadsby PJ, Ashina M, Al-Karagholi MA-M, Sinclair A, Mitsikostas D, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia. 2019;39(12):1475–87.

    PubMed  PubMed Central  Google Scholar 

  28. Schroeder CF, Möller M, May A. nVNS sham significantly affects the trigeminal-autonomic reflex. Neurology. 2019;93(5):e518–21 Important to understand the mechanism underlying nVNS.

    PubMed  Google Scholar 

  29. Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: preliminary findings from a prospective observational cohort study. J Headache Pain. 2015;16(1):101.

    PubMed  PubMed Central  Google Scholar 

  30. Magis D, D’Ostilio K, Thibaut A, De Pasqua V, Gerard P, Hustinx R, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia. 2017;37(9):881–91 Important to understand the mechanism underlying eTNS.

    PubMed  Google Scholar 

  31. Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gérard P, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80(8):697–704 Important trial for approval of eTNS for preventive therapy.

    PubMed  Google Scholar 

  32. Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial. Cephalalgia. 2019;39(1):3–14 Important trial for approval of eTNS for acute therapy.

    PubMed  Google Scholar 

  33. Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous Supraorbital NeuroStimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14(1):95 Important to understand the safety of eTNS.

    PubMed  PubMed Central  Google Scholar 

  34. Ristić D, Ellrich J. Innocuous peripheral nerve stimulation shifts stimulus–response function of painful laser stimulation in man. Neuromodulation. 2014;17(7):686–95.

    PubMed  Google Scholar 

  35. Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, et al. Remote electrical neuromodulation (REN) relieves acute migraine: a randomized, double-blind, placebo-controlled, multicenter trial. Headache. 2019;59(8):1240–52 Important trial for approval of eTNS.

    PubMed  PubMed Central  Google Scholar 

  36. Yarnitsky D, Volokh L, Ironi A, Weller B, Shor M, Shifrin A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017;88(13):1250–5.

    PubMed  Google Scholar 

  37. U.S. Food and Drug Administration. 2019 [cited 2020 Jun 28]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180059.pdf. Accessed 1 June 2020.

  38. Dieterich M, Brandt T. Functional brain imaging of peripheral and central vestibular disorders. Brain. 2008;131(10):2538–52.

    PubMed  Google Scholar 

  39. Marcelli V, Esposito F, Aragri A, Furia T, Riccardi P, Tosetti M, et al. Spatio-temporal pattern of vestibular information processing after brief caloric stimulation. Eur J Radiol. 2009;70(2):312–6.

    PubMed  Google Scholar 

  40. Wilkinson D, Ade KK, Rogers LL, Attix DK, Kuchibhatla M, Slade MD, et al. Preventing episodic migraine with caloric vestibular stimulation: a randomized controlled trial. Headache. 2017;57(7):1065–87.

    PubMed  Google Scholar 

  41. U.S. National Library of Medicine. [cited 2020 Jul 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT02991430. Accessed 1 June 2020.

  42. Black RD, Rogers LL, Ade KK, Nicoletto HA, Adkins HD, Laskowitz DT. Non-invasive neuromodulation using time-varying caloric vestibular stimulation. IEEE J Transl Eng Health Med. 2016;4:2168.

    Google Scholar 

  43. Reis DJ, Kobylarz K, Yamamoto S, Golanov EV. Brief electrical stimulation of cerebellar fastigial nucleus conditions long-lasting salvage from focal cerebral ischemia: conditioned central neurogenic neuroprotection. Brain Res. 1998;780(1):161–5.

    CAS  PubMed  Google Scholar 

  44. Golanov EV, Reis DJ. Neuroprotective electrical stimulation of cerebellar fastigial nucleus attenuates expression of periinfarction depolarizing waves (PIDs) and inhibits cortical spreading depression. Brain Res. 1999;818(2):304–15.

    CAS  PubMed  Google Scholar 

  45. Juan Y, Shu O, Jinhe L, Na Y, Yushuang D, Weiwei D, et al. Migraine prevention with percutaneous mastoid electrical stimulator: a randomized double-blind controlled trial. Cephalalgia. 2017;37(13):1248–56.

    PubMed  Google Scholar 

  46. Deng Y, Zheng M, He L, Yang J, Yu G, Wang J. A head-to-head comparison of percutaneous mastoid electrical stimulator and supraorbital transcutaneous stimulator in the prevention of migraine: a prospective, randomized controlled study. Neuromodulation. 2020 [cited 2020 Jul 7]; Available from:. https://doi.org/10.1111/ner.13127.

Download references

Acknowledgments

Figure 1: Icons made by Smashicons, Freepik, Pixel perfect at www.flaticon.com

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA

    Benzion Blech & Amaal J. Starling

Authors
  1. Benzion Blech
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amaal J. Starling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benzion Blech.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Episodic Migraine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blech, B., Starling, A.J. Noninvasive Neuromodulation in Migraine. Curr Pain Headache Rep 24, 78 (2020). https://doi.org/10.1007/s11916-020-00914-3

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11916-020-00914-3

Keywords

Search

Navigation